ESR1
ESR1 (estrogen Receptor 1), also known as estrogen receptor alpha (ERα), is a nuclear receptor encoded by the ESR1 gene on chromosome 6q25.1.
ESR1 (estrogen Receptor 1), also known as estrogen receptor alpha (ERα), is a nuclear receptor encoded by the ESR1 gene on chromosome 6q25.1. As a ligand-activated transcription factor it mediates the effects of estrogen by binding estrogen response elements in target gene promoters, regulating proliferation, differentiation and survival in breast, uterus, ovary, bone and liver. estrogen binding drives a conformational change that promotes dimerization, coactivator recruitment and transcription of genes governing cell-cycle progression and apoptosis suppression; a membrane-associated pool also signals within minutes through the PI3K/Akt signaling pathway and JAK2/STAT3 signaling pathway, independently of transcription.
Roughly 70–80% of breast cancers are estrogen receptor-positive, which makes the estrogen–ESR1 axis the principal target of endocrine therapy — though the drugs attack it at two different points. Aromatase inhibitors act on the enzyme CYP19A1 to cut estrogen synthesis, starving the receptor of ligand without touching it; selective estrogen receptor modulators such as tamoxifen bind the receptor itself and act as antagonists in breast tissue while remaining partial agonists elsewhere, which is why they carry an endometrial cancer risk; and selective estrogen receptor degraders bind and destroy it.
That distinction determines what happens at resistance. Under the selective pressure of estrogen deprivation, activating mutations in the ESR1 ligand-binding domain — Y537S and D538G most often — emerge in a substantial fraction of metastatic tumors and lock the receptor in an active conformation that no longer requires estrogen. Such tumors escape aromatase inhibitors entirely, since the problem is no longer ligand supply, while remaining partly susceptible to receptor-directed degraders; the mutations are detectable in circulating tumor DNA, and an oral degrader is approved specifically for this setting in breast cancer. Beyond oncology, ESR1 is implicated in reproductive disorders including polycystic ovary syndrome and endometriosis, and in metabolic and inflammatory conditions.
Where the papers sit
17 papers from the last 6 months study ESR1 directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 observational · 4 human data · 7 preclinical · 4 unclassified
Themes 3 themes
-
ESR1 Resistance in Breast Cancer
Endocrine-resistant breast cancer is driving development of ERα degraders that can suppress ESR1-mutant disease. Dual PROTACs, allosteric and orthosteric degraders, hydrophobic tags, and Tam-NHC-Gold(I) conjugates seek stronger activity than conventional tamoxifen-based therapy. Reported mechanisms include proteasomal ERα removal and downregulation of RAMP3/CALCR signaling. Phosphorylation profiles and PAM50 subtyping broaden the work toward biomarker-guided treatment, although several studies remain early or preclinical.
8 papers · 47.1%
-
ESR1 Testing and Targeted Therapy
ESR1 mutation testing is moving into routine management of ER-positive, HER2-negative metastatic breast cancer. Real-world studies track testing uptake, mutation prevalence, treatment patterns, and outcomes, with cell-free tumour DNA enabling longitudinal detection. Emerging oral SERDs and other endocrine-directed therapies are shifting care toward mutation-guided treatment after aromatase inhibitor resistance. Integration of testing with clinical decisions, access, and managed-care pathways remains an open implementation challenge.
6 papers · 35.3%
-
Phytochemical Network Pharmacology
Phytochemical research is using network pharmacology and molecular docking to connect multi-target compounds with disease mechanisms. AKT and CASP3 recur among predicted pathways and therapeutic targets in diabetic kidney disease and hepatocellular carcinoma. Nutraceutical formulas and plant extracts are being prioritised through integrated target and pathway mapping rather than single-target screening. The evidence remains mainly computational and hypothesis-generating, so biochemical and clinical validation is still needed.
3 papers · 17.6%
Papers
The 17 papers from the last 6 months that study ESR1 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
ESR1 Resistance in Breast Cancer (8)
- NeoGen-BC: A synergistic framework combining generative protein language models and multi-window deep learning for designing shared neoantigens in breast cancer. Biochemical and biophysical research communications · 10 Sept 2026 PMID 42721858
- A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593925
- Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer. Journal of medicinal chemistry · 7 Jul 2026 PMID 42411996
- NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer. European journal of medicinal chemistry · 2 Jul 2026 PMID 42391931
- Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway. Journal of medicinal chemistry · 30 Jun 2026 PMID 42378404
- Oestrogen receptor phosphorylation profiles and in silico PAM50 subtyping reflect sexual dimorphism in breast cancer. The journal of pathology. Clinical research · 23 Jun 2026 PMID 42333999
- ERα Agonist Protects Aged Female Mice From Sevoflurane Neurotoxicity via PTEN Nuclear Translocation. CNS neuroscience & therapeutics · 29 May 2026 PMID 42212628
- Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation. Angewandte Chemie (International ed. in English) · 26 May 2026 PMID 42189698
ESR1 Testing and Targeted Therapy (6)
- ESR1 mutations and endocrine resistance in ER-positive breast cancer: Molecular mechanisms, liquid biopsy, and emerging targeted therapies. Indian journal of cancer · 27 Oct 2026 PMID 42937403
- AMCP Market Insights: Managed care approaches to ESR1-mutated advanced breast cancer. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42809213
- Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024. Breast cancer research and treatment · 9 Sept 2026 PMID 42714697
- Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024. Breast cancer research and treatment · 9 Sept 2026 PMID 42714671
- Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2- Metastatic Breast Cancer. Molecular diagnosis & therapy · 8 Sept 2026 PMID 42709321
- SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer. JCO oncology practice · 7 Jul 2026 PMID 42413061
Phytochemical Network Pharmacology (3)
- Molecular mechanisms of phytochemicals from Zanthoxylum nitidum (Roxb.) DC. against hepatocellular carcinoma: insights from network pharmacology, molecular docking, and bioinformatics. Artificial cells, nanomedicine, and biotechnology · 24 Jul 2026 PMID 42498300
- Revealing the mechanism of heptamethoxyflavone against diabetic kidney disease: an integrated study combining network pharmacology, molecular docking and experimental validation. Biochemical and biophysical research communications · 13 Jul 2026 PMID 42442088
- A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. PloS one · 1 Jul 2026 PMID 42384725
By study type
Observational studies and case reports (2)
- Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024. Breast cancer research and treatment · 9 Sept 2026 PMID 42714697
- Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024. Breast cancer research and treatment · 9 Sept 2026 PMID 42714671
Human data, design not indexed (4)
- AMCP Market Insights: Managed care approaches to ESR1-mutated advanced breast cancer. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42809213
- NeoGen-BC: A synergistic framework combining generative protein language models and multi-window deep learning for designing shared neoantigens in breast cancer. Biochemical and biophysical research communications · 10 Sept 2026 PMID 42721858
- Molecular mechanisms of phytochemicals from Zanthoxylum nitidum (Roxb.) DC. against hepatocellular carcinoma: insights from network pharmacology, molecular docking, and bioinformatics. Artificial cells, nanomedicine, and biotechnology · 24 Jul 2026 PMID 42498300
- Oestrogen receptor phosphorylation profiles and in silico PAM50 subtyping reflect sexual dimorphism in breast cancer. The journal of pathology. Clinical research · 23 Jun 2026 PMID 42333999
Preclinical: animal, cell and lab studies (7)
- A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593925
- Revealing the mechanism of heptamethoxyflavone against diabetic kidney disease: an integrated study combining network pharmacology, molecular docking and experimental validation. Biochemical and biophysical research communications · 13 Jul 2026 PMID 42442088
- Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer. Journal of medicinal chemistry · 7 Jul 2026 PMID 42411996
- NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer. European journal of medicinal chemistry · 2 Jul 2026 PMID 42391931
- A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. PloS one · 1 Jul 2026 PMID 42384725
- Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway. Journal of medicinal chemistry · 30 Jun 2026 PMID 42378404
- ERα Agonist Protects Aged Female Mice From Sevoflurane Neurotoxicity via PTEN Nuclear Translocation. CNS neuroscience & therapeutics · 29 May 2026 PMID 42212628
Unclassified: not yet indexed with MeSH (4)
- ESR1 mutations and endocrine resistance in ER-positive breast cancer: Molecular mechanisms, liquid biopsy, and emerging targeted therapies. Indian journal of cancer · 27 Oct 2026 PMID 42937403
- Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2- Metastatic Breast Cancer. Molecular diagnosis & therapy · 8 Sept 2026 PMID 42709321
- SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer. JCO oncology practice · 7 Jul 2026 PMID 42413061
- Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation. Angewandte Chemie (International ed. in English) · 26 May 2026 PMID 42189698
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-11 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.